Edwards launches sapien 3 ultra resilia valve following fda approval

Irvine, calif. , sept. 12, 2022 /prnewswire/ -- edwards lifesciences (nyse: ew) today announced the launch of the sapien 3 ultra resilia valve, which incorporates edwards' breakthrough resilia tissue technology with the industry-leading sapien 3 ultra transcatheter aortic heart valve.

EW Ratings Summary

EW Quant Ranking